CN1538844A - 用作ccr受体活性调节剂的新型酰胺类化合物、其制备及治疗用途 - Google Patents

用作ccr受体活性调节剂的新型酰胺类化合物、其制备及治疗用途 Download PDF

Info

Publication number
CN1538844A
CN1538844A CNA028070968A CN02807096A CN1538844A CN 1538844 A CN1538844 A CN 1538844A CN A028070968 A CNA028070968 A CN A028070968A CN 02807096 A CN02807096 A CN 02807096A CN 1538844 A CN1538844 A CN 1538844A
Authority
CN
China
Prior art keywords
represent
alkyl
formula
group
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028070968A
Other languages
English (en)
Chinese (zh)
Inventor
�������ɭ
托马斯·埃里克森
���ɡ�������
卡罗林纳·拉威茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1538844A publication Critical patent/CN1538844A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CNA028070968A 2001-03-23 2002-03-19 用作ccr受体活性调节剂的新型酰胺类化合物、其制备及治疗用途 Pending CN1538844A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE01010388 2001-03-23
SE0101038A SE0101038D0 (sv) 2001-03-23 2001-03-23 Novel compounds

Publications (1)

Publication Number Publication Date
CN1538844A true CN1538844A (zh) 2004-10-20

Family

ID=20283509

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028070968A Pending CN1538844A (zh) 2001-03-23 2002-03-19 用作ccr受体活性调节剂的新型酰胺类化合物、其制备及治疗用途

Country Status (20)

Country Link
US (1) US7345063B2 (https=)
EP (1) EP1372651B1 (https=)
JP (1) JP2004524345A (https=)
KR (1) KR20030085030A (https=)
CN (1) CN1538844A (https=)
AT (1) ATE355842T1 (https=)
BR (1) BR0208336A (https=)
CA (1) CA2441933A1 (https=)
DE (1) DE60218641T2 (https=)
DK (1) DK1372651T3 (https=)
ES (1) ES2280511T3 (https=)
IL (1) IL157653A0 (https=)
MX (1) MXPA03008443A (https=)
NO (1) NO20034215L (https=)
NZ (1) NZ528296A (https=)
PT (1) PT1372651E (https=)
SE (1) SE0101038D0 (https=)
SI (1) SI1372651T1 (https=)
WO (1) WO2002076457A1 (https=)
ZA (1) ZA200306792B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US7005439B2 (en) * 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
NZ565040A (en) 2005-06-28 2010-05-28 Sanofi Aventis Isoquinoline derivatives as inhibitors of RHO-kinase
KR101373535B1 (ko) 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
JP5049970B2 (ja) 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
WO2008077555A2 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
KR20090092303A (ko) 2006-12-27 2009-08-31 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀린 유도체
HRP20131040T1 (hr) 2008-06-24 2013-12-06 Sanofi Bi- i policikliäśki supstituirani izokinolin i derivati izokinolina kao inhibitori rho-kinaze
CN102131784B (zh) 2008-06-24 2014-08-27 赛诺菲-安万特 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮
PT2313374E (pt) 2008-06-24 2013-11-29 Sanofi Sa Isoquinolinas e isoquinolinonas 6-substituídas

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US3577432A (en) 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US4029801A (en) 1970-09-03 1977-06-14 John Wyeth & Brother Limited Pharmaceutical compositions and methods of treating hypertension
JPS5511670B1 (https=) 1971-07-13 1980-03-26
US4080328A (en) 1971-07-13 1978-03-21 Sumitomo Chemical Company, Limited N-substituted heterocyclic derivatives and preparation thereof
US3755584A (en) 1972-04-03 1973-08-28 Abbott Lab Tranquilizers
FR2190430A1 (en) 1972-06-29 1974-02-01 Ferlux N-aminomethylhydroxamic acids - with antiinflammatory activity pre-pared by Mannich reaction
US3894030A (en) 1973-01-04 1975-07-08 Janssen Pharmaceutica Nv 1-{8 1-(2-Hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US3818017A (en) 1973-01-04 1974-06-18 Janssen Pharmaceutica Nv 1-{8 1-(2-hydroxy-3-aryloxypropyl)-4-piperidyl{9 -2-benzimidazolinones and related compounds
US4166119A (en) 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
WO1980000152A1 (fr) 1978-07-03 1980-02-07 Sandoz Ag Derives d'un 3-aminopropoxy-aryle, leur preparation et utilisation
US4264613A (en) 1979-08-01 1981-04-28 Science Union Et Cie, Societe Francaise De Recherche Medicale Piperidylbenzimidazolinone compounds
FR2469411A1 (fr) 1979-11-15 1981-05-22 Science Union & Cie Nouveaux derives de la piperidylbenzimidazolinone, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
EP0095454A3 (de) 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Neue kernsubstituierte Pyrogallol-Derivate
JPS59222484A (ja) 1983-06-02 1984-12-14 Kowa Co テトラヒドロナフチルカルボン酸フエニルエステル誘導体
US5614533A (en) 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
DE3723568C2 (de) 1987-07-16 1994-01-27 Siemens Ag Differenzstromschutzschalter
DE3723648A1 (de) 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
ES2027897A6 (es) 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina.
IL105716A0 (en) 1992-06-08 1993-09-22 Richter Gedeon Vegyeszet Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
IL106600A (en) 1992-08-07 1997-09-30 Sankyo Co Peptides, pharmaceutical compositions containing the same and processes for the preparation thereof
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
DE19703131A1 (de) 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
IL135488A0 (en) 1997-11-18 2001-05-20 Teijin Ltd Cyclic amine derivatives
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000053600A1 (en) 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivatives
US6518286B1 (en) 1999-03-26 2003-02-11 Astrazeneca Ab Compounds
CA2373607A1 (en) 1999-05-14 2000-11-23 Bristol-Myers Squibb Pharma Research Labs, Inc. Cyclic amine derivatives and their uses
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
JP4782342B2 (ja) * 1999-12-17 2011-09-28 サノフィ−アベンティス フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
FR2802533B1 (fr) * 1999-12-17 2002-02-15 Sanofi Synthelabo Phenoxypropanolamines, leur preparation et leur application en therapeutique
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
ES2280511T3 (es) 2007-09-16
US7345063B2 (en) 2008-03-18
JP2004524345A (ja) 2004-08-12
SE0101038D0 (sv) 2001-03-23
NO20034215L (no) 2003-11-24
EP1372651A1 (en) 2004-01-02
DE60218641D1 (de) 2007-04-19
NZ528296A (en) 2005-03-24
EP1372651B1 (en) 2007-03-07
KR20030085030A (ko) 2003-11-01
PT1372651E (pt) 2007-05-31
IL157653A0 (en) 2004-03-28
DK1372651T3 (da) 2007-05-29
WO2002076457A1 (en) 2002-10-03
ZA200306792B (en) 2004-11-29
SI1372651T1 (sl) 2007-06-30
BR0208336A (pt) 2004-03-23
DE60218641T2 (de) 2007-11-29
ATE355842T1 (de) 2007-03-15
MXPA03008443A (es) 2004-01-29
NO20034215D0 (no) 2003-09-22
US20040122020A1 (en) 2004-06-24
CA2441933A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
JP4022142B2 (ja) 新規化合物
CN1538844A (zh) 用作ccr受体活性调节剂的新型酰胺类化合物、其制备及治疗用途
CN1187326C (zh) 新化合物
CN1422269A (zh) 1h－咪唑并吡啶衍生物
CN1639159A (zh) N－氨基乙酰基－吡咯烷－2－腈和它们作为ddp－iv抑制剂的用途
CN1537111A (zh) 脲取代的咪唑并喹啉醚
CN1278790A (zh) 化合物
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1642913A (zh) 用作趋化因子受体活性(尤其是ccr5)调节剂的哌啶或8－氮杂－二环[3.2.1]辛－3－基衍生物
CN1274685C (zh) 苯并咪唑衍生物调节趋化因子受体
CN1678608A (zh) 新的神经肽yy5受体拮抗剂
CN1921858A (zh) 哌啶基烷基氨基甲酸酯衍生物、其制备方法及其作为faah酶抑制剂的应用
CN1234026A (zh) 用作神经激肽拮抗剂的哌嗪并衍生物
CN1447794A (zh) 新化合物
CN1167682C (zh) 毒蕈碱拮抗剂
CN1894232A (zh) 作为趋化因子受体活性调节剂的新三环螺衍生物
CN1859907A (zh) 作为黑素浓集激素受体的选择性拮抗剂用于治疗肥胖症和相关病症的氨基苯并咪唑类
CN1832745A (zh) 作为神经肽y5(npy5)配体用于治疗肥胖症的2－[4－(苯基氨基)－哌啶－1－基]－n－苯基－乙酰胺衍生物及相关化合物
CN1753877A (zh) 用于治疗或预防α－2B－肾上腺素受体介导疾病的化合物
HK1068272A (en) Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
JP2005501866A (ja) ケモカイン受容体活性のモジュレーターとしての新規ピペリジニル誘導体
TWI301487B (en) Novel compounds for use as modulators of chemokine receptor activity
CN1688584A (zh) 治疗肥胖和中枢神经系统疾病的选择性d1/d5受体拮抗剂
CN1071746C (zh) 具有氧化氮合成酶活性的脒衍生物
CN1620448A (zh) 3位被杂环取代的哌啶－2,6－二酮

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068272

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1068272

Country of ref document: HK